Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

How early should blood pressure control be achieved for optimal cardiovascular outcomes?

Journal of Human Hypertension volume 25, pages 211–217 (2011)Cite this article

Subjects

Abstract

As a consequence of the aging population and the increasing prevalence rates for conditions such as type 2 diabetes and chronic kidney disease (CKD), management of hypertension will be focusing more and more on the high-risk patient. Clinical practice guidelines for managing hypertension in the United States recommend a target blood pressure (BP) <130/80 mm Hg in patients with diabetes or CKD, notably lower than the 140/90-mm Hg threshold for the general hypertensive population. However, the optimal timeframe from initiation of antihypertensive therapy to attaining these levels of BP control and influencing cardiovascular outcomes is not as well defined. Overall, a series of landmark BP intervention trials in patients with hypertension and additional cardiovascular risk factors collectively support that achieving prompt BP control, ideally within 1–3 months, translates into improved cardiovascular outcomes. Although the consistency of the findings is encouraging, the strength of this conclusion is limited by the available data, which were derived from studies not designed to determine the definition or benefits of early BP reduction. In several of these studies, using a treatment approach with initial monotherapy or combination therapy has clearly demonstrated pronounced BP lowering and high BP control rates within an intensive timeframe of 3–6 months of therapy. Although these studies were not conducted exclusively in high-risk patients, subgroup analyses have demonstrated that the observed outcomes in the overall study populations apply to the diabetic and CKD subsets.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2009; 119: e21–e181.

    Google Scholar 

  2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

    Article  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  4. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. Blood Press 2009; 18: 308–347.

    Article  CAS  Google Scholar 

  5. Bakris GL, Sowers JR . ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) 2008; 10: 707–713.

    Article  Google Scholar 

  6. Sowers JR, Lastra G, Rocha R, Seifu Y, Crikelair N, Levy DG . Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich) 2008; 10: 668–676.

    Article  CAS  Google Scholar 

  7. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006; 8: 470–480.

    Article  CAS  Google Scholar 

  8. Bakris GL, Weir MR . Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5: 202–209.

    Article  CAS  Google Scholar 

  9. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS . Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007; 167: 2431–2436.

    Article  Google Scholar 

  10. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.

    Article  CAS  Google Scholar 

  11. Chatellier G, Ménard J . The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. J Hypertens 1997; 15: 217–219.

    Article  CAS  Google Scholar 

  12. Messerli FH . Safety of calcium antagonists: dissecting the evidence. Am J Cardiol 1996; 78: 19–23.

    Article  CAS  Google Scholar 

  13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–2997.

    Article  Google Scholar 

  14. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374–384.

    Article  CAS  Google Scholar 

  15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    Article  CAS  Google Scholar 

  16. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163–2168.

    Article  CAS  Google Scholar 

  17. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.

    Article  CAS  Google Scholar 

  18. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

    Article  Google Scholar 

  19. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

    Article  CAS  Google Scholar 

  20. Basile JN, Chrysant S . The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006; 20: 169–175.

    Article  CAS  Google Scholar 

  21. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V et al. The study on cognition and prognosis in the elderly (SCOPE)—major CV events and stroke in subgroups of patients. Blood Press 2005; 14: 31–37.

    Article  Google Scholar 

  22. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R et al. Clinical outcomes in the diabetes cohort of the international verapamil SR-trandolapril study. Hypertension 2004; 44: 637–642.

    Article  CAS  Google Scholar 

  23. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm Jr RH et al. Baseline characteristics and early blood pressure control in the convince trial. Hypertension 2001; 37: 12–18.

    Article  CAS  Google Scholar 

  24. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.

    Article  CAS  Google Scholar 

  25. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007; 16: 80–86.

    Article  Google Scholar 

  26. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–2428.

    Article  CAS  Google Scholar 

  27. Weber MA, Jamerson K, Bakris GL, Yelazquez EJ, Dahlöf B, Kelly RY et al. Cardiovascular events in patients with diabetes and hypertension receiving renin angiotensin system blockade plus a diuretic or a calcium channel blocker. J Am Coll Cardiol 2010 (e-pub ahead of print 29 June 2010).

  28. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH Study. Blood Press 2008; 17: 7–17.

    Article  CAS  Google Scholar 

  29. Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E et al. The diabetes subgroup baseline characteristics of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. J Cardiometab Syndr 2008; 3: 229–233.

    Article  Google Scholar 

  30. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.

    Article  CAS  Google Scholar 

  31. Arguedas JA, Perez MI, Wright JM . Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009; 3: Art. No.: CD004349 (doi:10.1002/14651858.CD004349.pub2).

  32. Kalaitzidis R, Bakris GL . Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich) 2009; 11: 345–347.

    Article  Google Scholar 

  33. Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R . Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20: 807–815.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The preparation of this paper was made possible by funding from Novartis Pharmaceuticals Corporation.

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

    M R Weir

  2. Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

    D Zappe

  3. Oxford PharmaGenesis Inc., Newtown, PA, USA

    L A Orloski

  4. Department of Cardiovascular Medicine, Diabetes and Cardiovascular Research Center, University of Missouri School of Medicine, Columbia, MO, USA

    J R Sowers

Authors
  1. M R Weir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Zappe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L A Orloski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J R Sowers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Weir.

Ethics declarations

Competing interests

Dr Weir is a scientific advisor for Novartis Pharmaceuticals Corporation, MSD, Boehringer-Ingelheim, Amgen, and Daiichi-Sankyo. Dr Zappe is an employee of Novartis Pharmaceuticals Corporation. Dr Orloski is an employee of Oxford PharmaGenesis Inc. Dr Sowers has research funding from NIH, VA, Novartis Pharmaceuticals Corporation, and Forest Laboratories and is a consultant to Novartis Pharmaceuticals Corporation and Forest Laboratories.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weir, M., Zappe, D., Orloski, L. et al. How early should blood pressure control be achieved for optimal cardiovascular outcomes?. J Hum Hypertens 25, 211–217 (2011). https://doi.org/10.1038/jhh.2010.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2010.64

Keywords

This article is cited by

Search

Advanced search

Quick links